BioCentury
ARTICLE | Clinical News

CERC-301: Completed Phase II enrollment

September 26, 2016 7:00 AM UTC

Cerecor completed enrollment of 115 patients in the double-blind, placebo-controlled, U.S. Phase II Clin301-203 trial evaluating 12 and 20 mg oral CERC-301 once weekly for 2 weeks. The trial enrolled ...